摘要
目的:在蛋白水平上研究国人弥漫性大B细胞淋巴瘤(diffuse large B-cell lymphoma,DLBCL)分子分型的蛋白表型特点,为DLBCL的病理诊断、预后和治疗提供依据。方法:取DLBCL标本52例行HE染色和免疫组化染色。在形态学分型的基础上,利用CD10、MUM1和bcl-6免疫标记对DLBCL进行分子分型,分为生发中心样B细胞样组(germi-nal center B-cell-like,GCB)和非生发中心样B细胞样组(non-germinal center B-cell-like,non-GCB),分析其在DLBCL中的构成比,及CD10、MUM1和bcl-6的表达情况。结果:本组DLBCL中,non-GCB的构成比超过GCB(69.2%/30.8%);统计学分析表明,GCB组间CD10、bcl-6、CD10/bcl-6的表达率的差异有显著性意义,其中CD10的表达率最高,bcl-6其次,CD10/bcl-6最低;non-GCB组间MUM1、MUM1/bcl-6的表达率的差异有显著性意义。结论:我国的DLBCL多起源于后生发中心B细胞,以non-GCB为主,预后较差。DLBCL在CD10、MUM1和bcl-6表达的差异对判定GCB组和non-GCB组有意义。
Objective： To investigate protein expression in the molecular subtypes of diffuse large B-cell lymphoma （DLBCL）, so as to provide discernible markers for the pathological diagnosis, treatment and prognosis of DLBCL. Methods： H＆E and immunohistochemical staining were performed on samples from 52 cases with DLBCL. On the basis of immunohistochemical staining, the cases of DLBCL were further subtyped molecularly into the germinal center B-cell-like （GCB） and ram-germinal center B-cell-like （non-GCB） groups, using CD10, MUM1 and bcl-6. Then the ratio of each subtype within DLBCL was analyzed in conjunction with the expression of CD10, MUM1 and bcl-6. Results： In this study, the number of non-GCB DLBCL eases was higher than the number of GCB DLBCL cases （69.2% versus 30.8%,）. Statistical analysis revealed a significant difference among the expression rates of CD10 alone, bcl-6 alone and CD10 and bcl-6 together in the GCB groups, in which the expression rate of CD10 ranked first, followed by bcl-6 and then CD10 and bcl-6 together. There was also a significant difference between the expression rates of MUM1 and MUM1 and bcl-6 together in the non-GCB groups. Conclusion： In China, most DLBCL cases originate from post-germinal center B-cells. The non-germinal center B-cell subtype is more prevalent and has a poorer prognosis. There was a significant difference in the expression of CD10, MUM1 and bcl-6 between the GCB and non-GCB groups that may be used for discrimination of the two subtypes.
出处
《中国肿瘤临床》
CAS
CSCD
北大核心
2007年第5期241-244,共4页
Chinese Journal of Clinical Oncology
基金
国家自然科学基金(编号:60372021)
福建省自然科学基金资助(编号:A0310010)
关键词
DLBCL
分子亚型
免疫组化
形态学亚型
预后
DLBCL Molecular subtype
Immunohistochemistry
Morphological subtype Prognosis
